Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients (Q50781541)

19 March 2018

title

Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients (English)

1 reference

19 March 2018

0 references

H L Zwibel

1

1 reference

19 March 2018

Copolymer-1 Treatment Study Principal Investigators

series ordinal

2

1 reference

19 March 2018

language of work or name

English

0 references

publication date

1 June 2006

1 reference

19 March 2018

Acta Neurologica Scandinavica

published in

1 reference

19 March 2018

volume

113

1 reference

19 March 2018

issue

6

1 reference

19 March 2018

page(s)

378-386

1 reference

19 March 2018

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

cites work

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.2006.00627.X

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.2006.00627.X

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.2006.00627.X

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.2006.00627.X

Early intervention with immunomodulatory agents in the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.2006.00627.X

Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.2006.00627.X

Steroid correlates of territorial behavior in male jacky dragons, Amphibolurus muricatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.2006.00627.X

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.2006.00627.X

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.2006.00627.X

Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.2006.00627.X

Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.2006.00627.X

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.2006.00627.X

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.2006.00627.X

Relapses and progression of disability in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.2006.00627.X

10.1111/J.1600-0404.2006.00627.X

21 January 2018

Identifiers

DOI

1 reference

19 March 2018

1 reference

19 March 2018